Lymphoma, T-Cell Clinical Trial
Official title:
Early Clinical Study of SENL101 Autologous T Cell Injection in the Treatment of Adult Patients With Relapsed or Refractory CD7+ Hematolymphoid Malignancies
To evaluate the tolerability and safety of SENL101 in patients with relapsed or refractory CD7+ hematolymphoid malignancies.
Status | Recruiting |
Enrollment | 18 |
Est. completion date | June 30, 2024 |
Est. primary completion date | December 30, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | The subjects of this study were patients with recurrent or refractory hematocratic malignancies of CD7+. Inclusion Criteria: 1. Subjects diagnosed with refractory/relapsing T-cell leukaemia/lymphoma met one of the following criteria: relapse: disease recurrence after complete remission with at least two prior regiments or complete remission with stem cell transplantation; Refractory: patients who have received at least two previous treatment regimens and failed to achieve a complete or partial response after the last treatment (leukemia patients), or failed to achieve a response after stem cell transplantation or develop disease progression; 2. The tumor cells detected by bone marrow flow cytometry were CD7+ and/or extramedullary lesions were diagnosed as CD7+ by pathological immunohistochemistry at the time of enrollment and screening; 3. If tumor cells were detected in peripheral blood during enrollment and screening, it was required to meet the requirement that the surface immunophenotype of tumor cells was CD4 and CD8 double negative by flow cytometry. If the surface phenotype of peripheral blood tumor cells was not CD4 and CD8 double negative, the proportion of tumor cells in peripheral blood was =1%; 4. Life expectancy greater than 12 weeks; 5. ECOG 0-2; 6. Age 18-65 (upper and lower limits included); 7. HGB at least 70g/L,PLT 20x109/L, can be transfused; 8. Liver and kidney functions The cardiopulmonary functions meet the following requirements: Oxygen saturation under air = 92%; LVEF=45%; Total bilirubin <3×ULN; ALT/AST<5×ULN; Creatinine <1.5×ULN; 9. Informed consent explained to, understood by and signed by patient/ guardian. Exclusion Criteria: Those who meet any of the following criteria are not eligible to join the group: 1. New York Heart Association (NYHA) classification = grade III heart failure or myocardial infarction, cardiac angioplasty or stenting, unstable angina pectoris or other clinically prominent heart disease within one year before signing the informed consent form, Or QTc interval >480ms at screening (QTc interval calculated by Fridericia formula); 2. If the patient has a history of hematopoietic stem cell transplantation, 6 months after the patient received allogeneic hematopoietic stem cell transplantation; 3. Those with active GvHD or those who require immunosuppressive therapy; 4. Malignancy other than T-cell acute lymphoblastic leukemia/lymphoma within 5 years prior to screening, except for adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer after radical surgery, radical surgery ductal carcinoma in situ; 5. Active or uncontrollable infection requiring systemic treatment within 7 days prior to screening (except for mild urogenital infections and upper respiratory tract infections); 6. History of autoimmune disease (eg, rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease) requiring systemic immunosuppressive/systemic disease modulating medication within the past 2 years; 7. When screening, if the hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HbcAb) is positive, and the peripheral blood hepatitis B virus (HBV) DNA is higher than the detection limit, it needs to be excluded; if the hepatitis C virus (HCV) antibody is positive, the peripheral blood HCV Those with positive RNA need to be excluded; those with positive human immunodeficiency virus (HIV) antibody; those with positive cytomegalovirus (CMV) DNA test; those with positive test for Treponema pallidum specific antibody (TPPA) need to be excluded; 8. Participate in other clinical trials within 4 weeks before the informed consent is signed, or the date of the informed consent is signed and the last medication of the drug is still within 5 half-lives of the drug (whichever is longer); 9. History of severe allergy to biological products; 10. Unstable systemic disease as judged by the investigator: including but not limited to severe liver, kidney or metabolic disease requiring drug therapy; 11. Pregnant or breastfeeding women, and female subjects planning pregnancy within 2 years of cell infusion or male subjects whose partner is planning pregnancy within 2 years of cell infusion; 12. Subjects who have received CAR-T therapy or other gene-modified cell therapy prior to screening; 13. Circumstances that the investigator believes may increase the risk to the subject or interfere with the results of the trial. |
Country | Name | City | State |
---|---|---|---|
China | Tongji Hospital | Wuhan | Hubei |
Lead Sponsor | Collaborator |
---|---|
Hebei Senlang Biotechnology Inc., Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Cytokine release | Changes from baseline in IFN-?, TNF-a, IL-2, IL-6, IL-10 | 12 months post CAR-T cells infusion | |
Other | CD7 positive cells in peripheral blood at each time point | Absolute value and ratio of CD7 positive cells (T cells NK cells) at each time point in peripheral blood | 12 months post CAR-T cells infusion | |
Other | T cell subsets | T cell subsets monitoring at each time point (CD4+ CD8+ CD4+/ CD8+ ratio) | 12 months post CAR-T cells infusion | |
Other | Immunogenicity endpoint | Detectable antibody concentration in serum at each time point | 12 months post CAR-T cells infusion | |
Other | T cell NK cell recovery time after treatment | Absolute value of T cells NK cells at each time point | 12 months post CAR-T cells infusion | |
Primary | Safety: Incidence and severity of adverse events | The incidence and severity of adverse events and adverse reactions from infusion to withdrawal or before the safety follow-up period | 24 months post CAR-T cells infusion |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05540340 -
A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant
|
Phase 1 | |
Completed |
NCT02158975 -
Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas
|
Phase 2 | |
Completed |
NCT00043368 -
PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)
|
Phase 2 | |
Completed |
NCT00069238 -
Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas
|
Phase 2 | |
Recruiting |
NCT04104776 -
A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03703375 -
Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma
|
Phase 3 | |
Recruiting |
NCT05476770 -
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
|
Phase 1 | |
Completed |
NCT00038376 -
Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies
|
Phase 2 | |
Recruiting |
NCT03161223 -
Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03902184 -
IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma
|
Phase 2 | |
Not yet recruiting |
NCT03910283 -
Leveraging Mindsets to Improve Health & Wellbeing in Patients With Cancer
|
N/A | |
Completed |
NCT04121507 -
ASTRAL- a Clinical Study to Assess the Efficacy and Toxicity of High-dose Chemotherapy
|
Phase 2 | |
Completed |
NCT04136275 -
CAR-37 T Cells In Hematologic Malignancies
|
Phase 1 | |
Recruiting |
NCT03921879 -
Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma
|
Phase 1 | |
Terminated |
NCT03154710 -
Relevance of a Web-mediated Follow up in Patients Having a Lymphoma With a High Risk of Relapse in Complete or Partial Response
|
N/A | |
Recruiting |
NCT05466318 -
ChiCGB vs BEAM in High-risk or R/R Lymphomas
|
Phase 3 | |
Recruiting |
NCT04928105 -
Senl-T7 CAR-T Cells for Treatment of Relapsed or Refractory CD7+ Lymphoma
|
N/A | |
Withdrawn |
NCT04233697 -
Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma
|
Phase 1 | |
Completed |
NCT01309789 -
A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms
|
Phase 1 | |
Recruiting |
NCT05557903 -
Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL
|
Phase 1 |